Page 148 of 178: studies 1,471 to 1,480 of 1,775, newest first. Back to the ketamine for depression overview
Mental Health Weekly February 25, 2019 Valerie A. Canady
A Food and Drug Administration (FDA) advisory committee earlier this month recommended the approval of a ketamine nasal spray treatment for adults with treatment‐resistant depression. Recent research has shown that ketamine treatment is gaining traction as an effective treatment for people struggling with depression.
Journal of Affective Disorders February 1, 2019 Leorey N Saligan, Cristan A Farmer, Elizabeth D. Ballard et al.
Fatigue and depression are closely associated. The purpose of this secondary analysis was to understand the relationships between depression and improvements in specific depression domains on the anti-fatigue effects of ketamine, which we previously reported. This secondary analysis re-evaluated data collected longitudinally from 39 patients with treatment-resistant Major Depressive Disorder...
Contemporary Clinical Trials February 1, 2019 S. Mathew, S. Wilkinson, Murat Altinay et al. 54 citations
Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side effects. Ketamine has...
Psychiatry Research Neuroimaging January 30, 2019 Allison C. Nugent, Kathleen E. Wills, Jessica R. Gilbert et al.
Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min...
Chronic Stress 2019 Ginetta Collo, Laura Cavalleri, Emilio Merlo Pich
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression are only partially understood. Reactivation of neural plasticity in prefrontal cortex has been considered critical in mediating the effects of standard antidepressants, but in treatment-resistant depression patients with severe anhedonia, other components of the affected brain circuits, for...
Pharmacology, Biochemistry, and Behavior 2019 Nian-nian Huang, Dongyu Hua, Gaofeng Zhan et al.
ABSTRACT Ketamine, an N‐methyl‐d‐aspartic acid receptor (NMDAR) antagonist, elicits rapid‐acting and sustained antidepressant effects in treatment‐resistant depressed patients. Accumulating evidence suggests that gut microbiota via the gut‐brain axis play a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. Here we investigated the...
Handbook of experimental pharmacology 2019 Nuri B Farber
Fifteen to thirty percent of patients with major depressive disorder do not respond to antidepressants that target the monoaminergic systems. NMDA antagonists are currently being actively investigated as a treatment for these patients. Ketamine is the most widely studied of the compounds. A brief infusion of a low dose of this agent produces rapid improvement in depressive symptoms that lasts...
Archives of Psychiatry and Behavioral Sciences 2019 Michael Hart, Zack Z. Cernovsky 1 citation
present study extends the application of ketamine to patients with history of not only chronic
Journal of Affective Disorders 2019 Dawn F. Ionescu, Kate H Bentley, M. Eikermann et al. 179 citations
BACKGROUND Several studies indicate that ketamine has rapid antidepressant effects in patients with treatment-resistant depression (TRD). The extent to which repeated doses of ketamine (versus placebo) reduce depression in the short and long term among outpatients with TRD and chronic, current suicidal ideation remains unknown. METHODS Twenty-six medicated outpatients with severe major...
Indian Journal of Psychiatry 2019 Suprio Mandal, VinodKumar Sinha, Nishant Goyal 92 citations
BACKGROUND: Severe depressive disorder is among most debilitating condition. Conventional pharmacotherapy usually takes several weeks (usually 4-12 weeks) to improve symptoms. Ketamine is an N-methyl-D aspartate receptor antagonist having rapid action on depressive symptoms. OBJECTIVES: The effect of subanesthetic dose of ketamine was assessed on depressive and anxiety symptoms. Illness...